Skip to main content
Caplight Logo









Glox Therapeutics

Glox Therapeutics

Private
GlasgowHealthcare & Life Scienceshttps://gloxtherapeutics.com/

Last Round

Grant

Jan 21, 2025

Total Funding Raised

$7.24M

Company Overview

Glox Therapeutics is a biotechnology company developing a pipeline of engineered precision bacteriocins targeting pathogens that cause serious infections associated with high levels of antimicrobial resistance (AMR).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

precision antibioticsantimicrobial resistanceAMRengineered bacteriocinssuperbugsnarrow-spectrum antibioticsdrug discovery platformdrug-resistant bacteriaprotein engineeringmicrobiome-sparingcystic fibrosis therapeuticsGram-negative bacteriahospital-acquired infectionspre-clinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Glox Therapeutics Comparables

Compare Glox Therapeutics with similar companies based on industry and business-model similarity.

Glox Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
DimiCare Biotech
81%
SNIPR Biome
79%
PrecisioBiotix Therapeutics
77%

Glox Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 21, 2025
GrantNov 20, 2024
SeedNov 14, 2023

Key People

Founding team and executive leadership

James Clark

Chief Executive Officer And Co Founder

Founding Team

Julie Lakin Assoc. CIPD

Office Manager & EA to CEO

Executive Team

Glox Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 19, 2025

    Grew 63% QoQ, from 8 to 13 employees.

  • Jun 6, 2025

    Grew 50% QoQ, from 8 to 12 employees.

Glox Therapeutics Filings

Explore SEC and related filing metadata, where available.

Glox Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Glox Therapeutics's valuation, stock price, and market status.

Is Glox Therapeutics a public or private company?

Glox Therapeutics is a private company.

What is the current stock price of Glox Therapeutics?

Glox Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Glox Therapeutics worth (valuation)?

Valuation information for Glox Therapeutics is not publicly available.

Can I buy Glox Therapeutics stock?

Glox Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Glox Therapeutics's last funding round?

Funding round information for Glox Therapeutics is not publicly available.

Who are the main investors in Glox Therapeutics?

Investor information for Glox Therapeutics is not publicly disclosed.

Will Glox Therapeutics IPO soon?

No public IPO plans have been announced for Glox Therapeutics.

How can I track Glox Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Glox Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersGlasgow
Employee Range12
Year Founded2023
Last FundingJan 21, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?